Paul B. Manning is Director & 10% Owner at Verrica Pharmaceuticals Inc. (VRCA). They have made 47 open-market trades across 7 companies since 2016, most recently 2026-06-16.
CIK 0001494695
44 open-market purchases totalling $191.9M since 2017, against 3 sales. Across 44 scored buys the stock is down 0.0% at ninety days, and 3.4 points behind the S&P over the same stretch.
44 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 52% | 48% | 34% |
| Avg Move | +4.1% | +1.6% | -0.0% |
| Alpha | +3.0% | +0.1% | -3.4% |
| Scored | 44 | 44 | 44 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LQDA | SELL | 2026-06-04 | 2026-06-08 | $63.91 | $12.8M | +10.1% | +23.2% | +4.9% |
| CADL | BUY | 2026-02-23 | 2026-02-26 | $5.45 | $3.0M | -7.8% | -19.3% | +45.4% |
| VRCA | BUY | 2025-11-25 | 2025-11-25 | $4.24 | $35.0M | +45.9% | +46.8% | +0.9% |
| LQDA | SELL | 2025-08-28 | 2025-09-02 | $28.26 | $37.9M | -8.0% | -22.5% | +13.5% |
| TSHA | BUY | 2025-05-30 | 2025-06-03 | $2.75 | $2.1M | -13.3% | -16.4% | -3.1% |
| CADL | BUY | 2024-12-16 | 2024-12-18 | $6.00 | $7.5M | +26.0% | -3.2% | +28.0% |
| LQDA | BUY | 2024-09-12 | 2024-09-16 | $8.90 | $6.0M | -2.0% | +12.4% | +6.6% |
| TSHA | BUY | 2024-06-27 | 2024-07-01 | $2.25 | $6.0M | +3.0% | -3.9% | -12.6% |
| LQDA | BUY | 2023-12-14 | 2023-12-18 | $7.16 | $4.0M | +56.2% | +74.4% | +102.1% |
| TSHA | BUY | 2023-11-17 | 2023-11-20 | $1.63 | $163K | +6.4% | -17.9% | +24.3% |
| TSHA | BUY | 2023-08-16 | 2023-08-16 | $0.90 | $29.6M | +19.0% | +64.5% | -33.5% |
| VRCA | BUY | 2023-07-24 | 2023-07-24 | $5.02 | $2.0M | -5.3% | -21.2% | -37.0% |
| TSHA | BUY | 2022-10-31 | 2022-11-02 | $2.00 | $3.0M | +22.8% | +24.3% | -13.2% |
| VRCA | BUY | 2022-07-05 | 2022-07-05 | $2.10 | $20.0M | +22.1% | +20.5% | +13.7% |
| LQDA | BUY | 2022-04-18 | 2022-04-19 | $5.10 | $4.0M | -3.5% | +2.5% | -33.9% |
| TSHA | BUY | 2022-02-02 | 2022-02-04 | $7.80 | $1.8M | -7.8% | -30.0% | -51.6% |
| VRCA | BUY | 2021-12-02 | 2021-12-06 | $9.36 | $936K | -10.3% | -11.5% | -25.6% |
| TSHA | BUY | 2021-11-24 | 2021-11-29 | $13.19 | $29K | +15.8% | -6.8% | -48.1% |
| TSHA | BUY | 2021-11-23 | 2021-11-24 | $12.54 | $502K | +10.5% | -3.3% | -53.3% |
| CADL | BUY | 2021-07-29 | 2021-08-04 | $8.00 | $13.0M | -4.6% | +6.7% | +47.0% |
| CADL | BUY | 2021-07-27 | 2021-07-29 | $7.36 | $265K | +5.4% | +6.9% | +54.8% |
| ABOS | BUY | 2021-07-06 | 2021-07-08 | $16.00 | $5.0M | +4.1% | -15.4% | -16.5% |
| TSHA | BUY | 2021-05-14 | 2021-05-17 | $20.98 | $252K | +0.5% | +11.0% | -29.7% |
| LQDA | BUY | 2021-04-13 | 2021-04-15 | $2.52 | $1.0M | +3.3% | +0.0% | -7.3% |
| VRCA | BUY | 2021-03-25 | 2021-03-29 | $14.75 | $21.8M | +0.5% | -2.5% | -14.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total | $480.0M |
Shares reported on the most recent Form 4, priced at the 2026-06-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.